Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

ERG protein expression over time from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hypoxia-inducible factor 1α predicts recurrence in high-grade soft tissue sarcoma of extremities and trunk wall

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Prevalence of human papillomavirus in squamous cell carcinomas of the soft palate

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIMS: We evaluated the consistency in ERG protein expression from diagnostic specimens through rebiopsies to radical prostatectomies in patients with clinically localised prostate cancer to investigate the validity of ERG status in biopsies.

METHODS: ERG expression was assessed by immunohistochemistry (IHC) in 625 biopsy sets and 86 radical prostatectomy specimens from 265 patients with prostate cancer managed on active surveillance. For IHC, a rabbit monoclonal primary antibody was used (clone: EPR3864). TMPRSS2-ERG fluorescence in situ hybridisation (FISH) analyses were performed in 74 biopsies using the FISH ZytoLight TriCheck Probe (SPEC ERG/TMPRSS2). FISH results were correlated with IHC findings.

RESULTS: The concordance between FISH and IHC was 97.3% and IHC demonstrated a sensitivity and specificity for ERG rearrangement of 100% and 95.5%, respectively. Applying IHC, 38.1% of patients were ERG-positive, 53.6% were ERG-negative and 8.3% showed both ERG-positive and negative tumour foci (ERG heterogeneous) at diagnosis. When ERG status was dichotomised (ERG-positive or heterogeneous vs ERG-negative), 95.6%-97.1% of patients did not experience ERG reclassification during the first two rounds of rebiopsies. The concordance in ERG status between biopsies and surgical specimen was 89.5%-94.2% depending on the number of rebiopsies included. Sampling bias was assumed to explain most (81.3%) of the mismatches in ERG status.

CONCLUSIONS: Consistency in ERG status ranged from 90% to 95% for patients undergoing serial biopsies and radical prostatectomy. This indicates that biopsies can be used reliably to investigate ERG's prognostic and predictive value.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Pathology
Vol/bind68
Udgave nummer10
Sider (fra-til)788-94
Antal sider7
ISSN0021-9746
DOI
StatusUdgivet - okt. 2015

ID: 45853588